Antidepressant prevalence for youths

A multi-national camparison

Julie M. Zito, Hilde Tobi, Lolkje T W de Jong-van den Berg, Joerg M. Fegert, Daniel J. Safer, Katrin Janhsen, Dorte Gilså Hansen, James F. Gardner, Gerd Glaeske

Research output: Contribution to journalArticle

Abstract

Objective: To compare antidepressant prevalence data in youths across three western European countries (Denmark, Germany, and the Netherlands) with US regional data in terms of age and gender and to show proportional subclass antidepressant (ATD) use. Method: A population-based analysis of administrative claims data for the year 2000 was undertaken in 0 to 19-year-old enrollees who were part of the insured populations from four countries having a total of from 72,570 to 480,680 members. Results: ATD medication utilization in the US dataset (1.63%) exceeded that of three Western European countries (prevalence ranged from 0.11 to 0.54%) by at least 3-fold. There were major variations in the use of subclasses: tricyclic antidepressants (TCAs) predominated in Germany while selective serotonin reuptake inhibitors (SSRIs) predominated in the US, Denmark and the Netherlands. Conclusions: Cross-national variations should be further explored to understand the factors related to these differences and how prevalence differences relate to effectiveness and safety. Community-based cohorts should be followed to establish outcomes in the usual practice setting.

Original languageEnglish (US)
Pages (from-to)793-798
Number of pages6
JournalPharmacoepidemiology and Drug Safety
Volume15
Issue number11
DOIs
StatePublished - Nov 2006

Fingerprint

Antidepressive Agents
Denmark
Netherlands
Germany
Insurance Claim Review
Tricyclic Antidepressive Agents
Serotonin Uptake Inhibitors
Population
Safety
Datasets

Keywords

  • antidepressants
  • Children and adolescents
  • Pharmacoepidemiology

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Zito, J. M., Tobi, H., de Jong-van den Berg, L. T. W., Fegert, J. M., Safer, D. J., Janhsen, K., ... Glaeske, G. (2006). Antidepressant prevalence for youths: A multi-national camparison. Pharmacoepidemiology and Drug Safety, 15(11), 793-798. https://doi.org/10.1002/pds.1254

Antidepressant prevalence for youths : A multi-national camparison. / Zito, Julie M.; Tobi, Hilde; de Jong-van den Berg, Lolkje T W; Fegert, Joerg M.; Safer, Daniel J.; Janhsen, Katrin; Gilså Hansen, Dorte; Gardner, James F.; Glaeske, Gerd.

In: Pharmacoepidemiology and Drug Safety, Vol. 15, No. 11, 11.2006, p. 793-798.

Research output: Contribution to journalArticle

Zito, JM, Tobi, H, de Jong-van den Berg, LTW, Fegert, JM, Safer, DJ, Janhsen, K, Gilså Hansen, D, Gardner, JF & Glaeske, G 2006, 'Antidepressant prevalence for youths: A multi-national camparison', Pharmacoepidemiology and Drug Safety, vol. 15, no. 11, pp. 793-798. https://doi.org/10.1002/pds.1254
Zito JM, Tobi H, de Jong-van den Berg LTW, Fegert JM, Safer DJ, Janhsen K et al. Antidepressant prevalence for youths: A multi-national camparison. Pharmacoepidemiology and Drug Safety. 2006 Nov;15(11):793-798. https://doi.org/10.1002/pds.1254
Zito, Julie M. ; Tobi, Hilde ; de Jong-van den Berg, Lolkje T W ; Fegert, Joerg M. ; Safer, Daniel J. ; Janhsen, Katrin ; Gilså Hansen, Dorte ; Gardner, James F. ; Glaeske, Gerd. / Antidepressant prevalence for youths : A multi-national camparison. In: Pharmacoepidemiology and Drug Safety. 2006 ; Vol. 15, No. 11. pp. 793-798.
@article{440bd3c32d94495d85301fc03d988028,
title = "Antidepressant prevalence for youths: A multi-national camparison",
abstract = "Objective: To compare antidepressant prevalence data in youths across three western European countries (Denmark, Germany, and the Netherlands) with US regional data in terms of age and gender and to show proportional subclass antidepressant (ATD) use. Method: A population-based analysis of administrative claims data for the year 2000 was undertaken in 0 to 19-year-old enrollees who were part of the insured populations from four countries having a total of from 72,570 to 480,680 members. Results: ATD medication utilization in the US dataset (1.63{\%}) exceeded that of three Western European countries (prevalence ranged from 0.11 to 0.54{\%}) by at least 3-fold. There were major variations in the use of subclasses: tricyclic antidepressants (TCAs) predominated in Germany while selective serotonin reuptake inhibitors (SSRIs) predominated in the US, Denmark and the Netherlands. Conclusions: Cross-national variations should be further explored to understand the factors related to these differences and how prevalence differences relate to effectiveness and safety. Community-based cohorts should be followed to establish outcomes in the usual practice setting.",
keywords = "antidepressants, Children and adolescents, Pharmacoepidemiology",
author = "Zito, {Julie M.} and Hilde Tobi and {de Jong-van den Berg}, {Lolkje T W} and Fegert, {Joerg M.} and Safer, {Daniel J.} and Katrin Janhsen and {Gils{\aa} Hansen}, Dorte and Gardner, {James F.} and Gerd Glaeske",
year = "2006",
month = "11",
doi = "10.1002/pds.1254",
language = "English (US)",
volume = "15",
pages = "793--798",
journal = "Pharmacoepidemiology and Drug Safety",
issn = "1053-8569",
publisher = "John Wiley and Sons Ltd",
number = "11",

}

TY - JOUR

T1 - Antidepressant prevalence for youths

T2 - A multi-national camparison

AU - Zito, Julie M.

AU - Tobi, Hilde

AU - de Jong-van den Berg, Lolkje T W

AU - Fegert, Joerg M.

AU - Safer, Daniel J.

AU - Janhsen, Katrin

AU - Gilså Hansen, Dorte

AU - Gardner, James F.

AU - Glaeske, Gerd

PY - 2006/11

Y1 - 2006/11

N2 - Objective: To compare antidepressant prevalence data in youths across three western European countries (Denmark, Germany, and the Netherlands) with US regional data in terms of age and gender and to show proportional subclass antidepressant (ATD) use. Method: A population-based analysis of administrative claims data for the year 2000 was undertaken in 0 to 19-year-old enrollees who were part of the insured populations from four countries having a total of from 72,570 to 480,680 members. Results: ATD medication utilization in the US dataset (1.63%) exceeded that of three Western European countries (prevalence ranged from 0.11 to 0.54%) by at least 3-fold. There were major variations in the use of subclasses: tricyclic antidepressants (TCAs) predominated in Germany while selective serotonin reuptake inhibitors (SSRIs) predominated in the US, Denmark and the Netherlands. Conclusions: Cross-national variations should be further explored to understand the factors related to these differences and how prevalence differences relate to effectiveness and safety. Community-based cohorts should be followed to establish outcomes in the usual practice setting.

AB - Objective: To compare antidepressant prevalence data in youths across three western European countries (Denmark, Germany, and the Netherlands) with US regional data in terms of age and gender and to show proportional subclass antidepressant (ATD) use. Method: A population-based analysis of administrative claims data for the year 2000 was undertaken in 0 to 19-year-old enrollees who were part of the insured populations from four countries having a total of from 72,570 to 480,680 members. Results: ATD medication utilization in the US dataset (1.63%) exceeded that of three Western European countries (prevalence ranged from 0.11 to 0.54%) by at least 3-fold. There were major variations in the use of subclasses: tricyclic antidepressants (TCAs) predominated in Germany while selective serotonin reuptake inhibitors (SSRIs) predominated in the US, Denmark and the Netherlands. Conclusions: Cross-national variations should be further explored to understand the factors related to these differences and how prevalence differences relate to effectiveness and safety. Community-based cohorts should be followed to establish outcomes in the usual practice setting.

KW - antidepressants

KW - Children and adolescents

KW - Pharmacoepidemiology

UR - http://www.scopus.com/inward/record.url?scp=33751103903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751103903&partnerID=8YFLogxK

U2 - 10.1002/pds.1254

DO - 10.1002/pds.1254

M3 - Article

VL - 15

SP - 793

EP - 798

JO - Pharmacoepidemiology and Drug Safety

JF - Pharmacoepidemiology and Drug Safety

SN - 1053-8569

IS - 11

ER -